CA2626085C - S-omeprazole strontium ou hydrate de ce compose, methode de synthese et preparation pharmaceutique le comprenant - Google Patents

S-omeprazole strontium ou hydrate de ce compose, methode de synthese et preparation pharmaceutique le comprenant Download PDF

Info

Publication number
CA2626085C
CA2626085C CA2626085A CA2626085A CA2626085C CA 2626085 C CA2626085 C CA 2626085C CA 2626085 A CA2626085 A CA 2626085A CA 2626085 A CA2626085 A CA 2626085A CA 2626085 C CA2626085 C CA 2626085C
Authority
CA
Canada
Prior art keywords
strontium
omeprazole
crystalline
tetrahydrate
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2626085A
Other languages
English (en)
Other versions
CA2626085A1 (fr
Inventor
Tae Hee Ha
Hee Sook Oh
Won Jeoung Kim
Chang Hee Park
Eun Young Kim
Young Hoon Kim
Kwee Hyun Suh
Gwan Sun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of CA2626085A1 publication Critical patent/CA2626085A1/fr
Application granted granted Critical
Publication of CA2626085C publication Critical patent/CA2626085C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2626085A 2005-10-26 2006-10-25 S-omeprazole strontium ou hydrate de ce compose, methode de synthese et preparation pharmaceutique le comprenant Expired - Fee Related CA2626085C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20050101059 2005-10-26
KR10-2005-0101059 2005-10-26
KRPCT/KR2006/000760 2006-03-06
KR2006000760 2006-03-06
PCT/KR2006/004369 WO2007049914A1 (fr) 2005-10-26 2006-10-25 S-omeprazole strontium ou hydrate de ce composé, méthode de synthèse et préparation pharmaceutique le comprenant

Publications (2)

Publication Number Publication Date
CA2626085A1 CA2626085A1 (fr) 2007-05-03
CA2626085C true CA2626085C (fr) 2011-12-06

Family

ID=37967988

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2626085A Expired - Fee Related CA2626085C (fr) 2005-10-26 2006-10-25 S-omeprazole strontium ou hydrate de ce compose, methode de synthese et preparation pharmaceutique le comprenant

Country Status (8)

Country Link
JP (1) JP5017274B2 (fr)
AU (1) AU2006306906B2 (fr)
CA (1) CA2626085C (fr)
IL (1) IL190709A (fr)
MY (1) MY140986A (fr)
NO (1) NO20082358L (fr)
RU (1) RU2372345C1 (fr)
WO (1) WO2007049914A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
CN116102538B (zh) * 2023-01-29 2024-10-18 山东省分析测试中心 一种转晶制备三水合艾司奥美拉唑镁的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
WO2004099182A1 (fr) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Sel de zinc de (s)-omeprazole
US20060189590A1 (en) * 2003-07-23 2006-08-24 Bernhard Kohl Alkaline salts of proton pump inhibitors
EP1885711A1 (fr) * 2005-05-06 2008-02-13 Glenmark Pharmaceuticals Limited Sel de strontium d'esomeprazole, procede de preparation de ce sel et compositions pharmaceutiques le contenant

Also Published As

Publication number Publication date
CA2626085A1 (fr) 2007-05-03
MY140986A (en) 2010-02-12
JP2009513625A (ja) 2009-04-02
IL190709A0 (en) 2008-11-03
NO20082358L (no) 2008-07-25
RU2372345C1 (ru) 2009-11-10
IL190709A (en) 2012-03-29
JP5017274B2 (ja) 2012-09-05
WO2007049914A1 (fr) 2007-05-03
AU2006306906A1 (en) 2007-05-03
AU2006306906B2 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
US8586752B1 (en) Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
CA2597632C (fr) Derives de sulfoxyde substitues, methodes de synthese desdits derives et applications desdits derives
US20060135565A1 (en) Crystalline form of rabeprazole sodium
CA2626085C (fr) S-omeprazole strontium ou hydrate de ce compose, methode de synthese et preparation pharmaceutique le comprenant
US8592601B2 (en) Precursor phase and use thereof for preparing the magnesium tetrahydrate salt of an omeprazole enantiomer
MXPA05001168A (es) Sal de (s)-pantoprazol y sus hidratos.
WO2006001755A1 (fr) Nouvelle forme modifiee de cristaux de sels d'esomeprazole sodium
CA2504796A1 (fr) Formes polymorphes du sel sodique du pantoprazole et procede pour leur preparation
US9034904B2 (en) Forms of dexlansoprazole and processes for the preparation thereof
KR101459088B1 (ko) 알-라베프라졸, 이의 금속염의 제조방법
KR20130063762A (ko) 신규 에스라베프라졸, 이의 알칼리금속 및 알칼리토금속염 및 이의 제조방법
CZ12613U1 (cs) Chemická sloučenina amlodipinaspartát a farmaceutický prostředek

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181025